Business Context and Reporting Period
This Form 8-K is a current report filed by Landec Corporation (not Lifecore Biomedical, Inc.) on March 8, 2021, covering events occurring on March 2, 2021. The filing discloses the separation of a senior executive officer.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to executive severance compensation:
- Severance Salary Continuation: $309,000 (aggregate for 12 months).
- Pro Rata Cash Incentive: Amount not specified in the text.
- Healthcare Continuation: Up to 12 months.
- Equity Acceleration: Stock options and restricted stock units vesting as if the executive remained employed for 12 months post-separation.
Material Changes
The material change reported is the departure of Dawn Kimball, Senior Vice President and Chief People Officer, effective March 12, 2021. This departure triggers specific compensatory arrangements under her employment agreement.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, or management commentary regarding business operations. The primary contingency noted is that the severance payments and benefits are conditional upon Ms. Kimball not revoking the Separation Agreement by March 11, 2021.
Investor Verification Checklist
- Verify the correct registrant name is Landec Corporation (LNDC), not Lifecore Biomedical, Inc.
- Confirm the effective separation date of March 12, 2021.
- Review the attached Exhibit 10.1 (Separation Agreement) for the full terms of the pro rata cash incentive and specific equity vesting calculations.
- Monitor for any subsequent filings regarding the appointment of a replacement Chief People Officer.